AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) …
Canaccord Genuity’s healthcare analyst John Newman weighed in today with his views on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), after the company reported that the FDA is requesting …
In a research report released Tuesday, Canaccord Genuity analyst John Newman maintained a Hold rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with an $8.00 price target, …
In a research report issued today, Canaccord Genuity analyst John Newman maintained a Hold rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with an $8 price target, …
Roth Capital analyst Ed Arce is out with his second note this week on Acelrx Pharmaceuticals (NASDAQ:ACRX) maintaining a Neutral rating with a $6 price target, following …
Roth Capital analyst Ed Arce reaffirmed a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a $6 price target, as the company announced that CEO Richard …
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a price target …
In a report issued yesterday, Canaccord Genuity analyst John Newman assigned a Hold rating on shares of AcelRx Pharmaceuticals (ACRX) with a price target of $8, following ACRX’s Zalviso …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) and reduced his price target to $16 (from $22), following …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a $22 price target, which represents 121% upside to the current share …